Corbus Pharmaceuticals Advances Obesity Drug CRB-913 into Critical Phase 1b Trial — Corbus Pharmaceuticals Holdings, Inc.

Event summary

Corbus Pharmaceuticals has completed enrollment in the CANYON-1 Phase 1b trial for CRB-913, an obesity treatment, with data expected in summer 2026.
The 16-week study involves 240 non-diabetic obese participants across four cohorts, including a placebo group.
CRB-913 is a once-daily oral CB1 inverse agonist, distinct from GLP-1 drugs, aiming to address treatment gaps in obesity management.
Phase 1a results showed a 2.9% placebo-adjusted weight loss in obese participants after 14 days, with no significant GI side effects.

The big picture

Corbus Pharmaceuticals is betting on CRB-913 as a non-incretin alternative in the obesity market, where GLP-1 drugs dominate but leave significant unmet needs. The Phase 1b trial results will be critical in determining whether CRB-913 can carve out a niche in a space crowded with established and emerging therapies. Success could position Corbus as a key player in obesity treatment, while failure may force a pivot in its strategic focus.

What we're watching

Clinical Efficacy: Whether CRB-913 can demonstrate superior or complementary efficacy to existing GLP-1 therapies in Phase 1b results.
Market Differentiation: The potential of CRB-913 to address the 40% of patients intolerant or non-responsive to incretin therapies.
Regulatory Pathway: The pace at which Corbus can advance CRB-913 into later-stage trials given the competitive obesity drug landscape.